• Investopedia2 days ago

    Mast Therapeutics, Philips Make Supply Deal (MSTX)

    Mast Therapeutics agreed to offer its AIR001 heart-failure drug using Philips Respironics' nebulizer drug delivery system.

  • Marketwired2 days ago

    FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial

    FluoroPharma Medical Inc. announced today that it has been collaborating with Philips for data management in conjunction with its Phase II clinical trials for its lead agent CardioPET . Safety and image ...

  • PR Newswire3 days ago

    Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001

    SAN DIEGO, Oct. 17, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into a collaborative agreement with Philips Respironics, Inc., the sleep and respiratory care business of Royal Philips (NYSE: PHG, AEX: PHIA) related to the supply of Philips' I-neb® Adaptive Aersol Delivery (AAD™) devices and related consumables for the nebulized delivery of the Company's lead product candidate, AIR001, a sodium nitrite solution for intermittent inhalation. "As we announced last month, we are accelerating activities related to our AIR001 program with support for ongoing, investigator-sponsored Phase 2 clinical studies of AIR001 being conducted at three separate prestigious research institutions," said Brian M. Culley, Chief Executive Officer of Mast.